Skip to main content
SpringerLink
Log in

Risk of serious infections higher with abatacept use for RA

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. A serious infection was defined as an infection occurring during treatment with abatacept or during the 3 months after withdrawal of abatacept without any initiation of a new biological agent and requiring hospitalisation and/or IV antibacterials and/or resulting in death.

Reference

  • Salmon JH, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Annals of the Rheumatic Diseases : [6 pages], 5 Jun 2015. Available from: URL: http://doi.org/10.1136/annrheumdis-2015-207362

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of serious infections higher with abatacept use for RA. Reactions Weekly 1558, 12 (2015). https://doi.org/10.1007/s40278-015-3001-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-3001-8

Search

Navigation